Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

tDCS and tACS: Research Evidence

What research shows for transcranial direct current stimulation (tDCS) and alternating current stimulation (tACS), including one FDA-approved depression product and why its approval does not extend to other devices.

Content last updated . This page has not been medically reviewed.

Back to Emerging Wellness Science

What these are

Transcranial direct current stimulation (tDCS) delivers low-intensity direct electrical current to specific areas of the brain through electrodes placed on the scalp. [1] Transcranial alternating current stimulation (tACS) is a related research approach studied as a way to modulate neural oscillations, for example in depression. [2] Both are different from magnetic stimulation; see electrical and magnetic brain stimulation.

Evidence labels (established, promising but limited, mixed, insufficient evidence, no good evidence of benefit, marketing claim) are explained in how we label evidence. This page gives no stimulation settings and is not a how-to.

Research by use

UseWhat the research reportsLabel
Depression (broader trials)A network meta-analysis of 113 trials linked tDCS to higher response than sham (odds ratio 2.65, 95% CI 1.55 to 4.55). [4] In a trial of 245 people, tDCS did not show noninferiority to escitalopram over 10 weeks and had more adverse events. [5]Promising but limited; mixed
Treatment-resistant depressionA 2026 meta-analysis found six small trials (200 people) that were inconsistent and highly heterogeneous. [6]Insufficient evidence
After strokeA Cochrane review of 67 studies (1,729 patients) found evidence of very low to moderate quality for daily activities, which did not hold when only trials with proper allocation concealment were included; it found no effect on arm function, leg function, muscle strength or cognition. [7]Mixed; no good evidence of benefit for arm function
Cognition in healthy adultsA review of single-session studies found no significant effect in any of 59 analyses. [8]No good evidence of benefit
tACS for depressionNine randomized trials; no significant reduction in clinician-rated severity, though higher odds of response and remission; certainty very low to moderate; authors say routine clinical use cannot be recommended. [2]Insufficient evidence
tACS and memory in older adultsFourteen randomized trials; authors call for larger trials and for work on optimal parameters. [9]Insufficient evidence

Brain-signal findings are weaker still. A systematic review found tDCS had a reliable effect on only one of 30 neurophysiological measures in healthy adults, motor-evoked potential size. [10] See clinical outcomes vs brain-signal changes.

Frequently asked questions

Is tDCS FDA approved?

One headset, the Flow FL-100, was approved on December 8, 2025 for moderate to severe depression in a defined group of adults. [1] That does not cover other devices.

Does tDCS work for depression?

Evidence is mixed. A large network meta-analysis favored tDCS over sham [4], but tDCS did not show noninferiority to escitalopram in one trial [5], and the FDA noted uncertainty of benefit because of unblinding. [1]

Can tDCS improve memory or focus in healthy people?

A quantitative review found no significant effect in 59 analyses of single-session studies. [8]

What is the difference between tDCS and tACS?

tDCS uses direct current. [1] tACS is studied for modulating neural oscillations. [2] Its evidence is much thinner.

Can it burn the skin?

Yes. In the FDA summary, two participants had first-degree skin burns while using dried-out pads. [1]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

One regulator record, read closely (United States)
The FDA approved one tDCS headset, the Flow FL-100, through premarket approval P230024, with a Notice of Approval dated December 8, 2025. [1] The FDA database lists it as a cranial electrotherapy stimulator to treat depression. [3]
  • Approved use: treatment of moderate to severe major depressive disorder in the current episode, alone or added to other treatment, in people 18 and older who are not considered treatment refractory to medication. [1]
  • The trial behind it: a double-blinded, randomized, sham-controlled study; the modified intention-to-treat group had 173 people. [1]
  • Result: on the Hamilton depression scale (HDRS-17), mean change was -9.4 with active stimulation and -7.1 with sham, a difference of -2.3 points. [1] That is a depression rating-scale score, not a direct measure of daily functioning.
  • FDA's own caution: the summary states a moderate level of uncertainty of benefit due to unblinding, and the summary also lists conflicting results in the literature and no prespecified clinically significant change as reasons. [1] Unblinding was visible: 77.6% in the active group correctly guessed their group, versus 40.7% of the sham group. [1]
  • Adverse effects: skin redness was reported by 63.5% of the active group and 18.5% of the sham group; two active-group participants had first-degree skin burns, each reporting dried-out pads, and no serious adverse events were attributed to the device. [1]
  • Contraindications: open wounds or damaged skin at the electrode site, and metallic skull reconstruction at the electrode site. [1]

This approval is for this product and this indication. It does not make other tDCS or "brain stimulation" headsets approved, effective or interchangeable. Status of other tDCS products was not verified for this page. See device-specific approval and clinical vs consumer devices.

Who should check first
Anyone with skin damage at the electrode site, metal in the skull or a history of seizures should talk with a clinician before any stimulation. Do-it-yourself builds and consumer headsets raise separate risks; see DIY stimulation risks. Consumer-device comparisons are in the Biohacking area.
Safety note
Depression needs professional care. Do not stop or change a medicine because of this page. In the United States, 988 reaches the Suicide and Crisis Lifeline; call 911 in an emergency.
References
  1. U.S. Food and Drug Administration. PMA P230024: Summary of Safety and Effectiveness Data (Flow FL-100). Read 2026-10-22.
  2. Nabil Y, et al. Transcranial alternating current stimulation for major depressive disorder: An updated systematic review and meta-analysis of randomized trials with GRADE assessment. J Affect Disord. 2026. Read 2026-10-22.
  3. U.S. Food and Drug Administration. PMA database record P230024 (Flow FL-100). Read 2026-10-22.
  4. Mutz J, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019. Read 2026-10-22.
  5. Brunoni AR, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med. 2017. Read 2026-10-22.
  6. Moshfeghinia R, et al. Efficacy and safety of transcranial direct current stimulation (tDCS) on treatment-resistant depression (TRD): A systematic review and meta-analysis of randomized clinical trials. J Affect Disord. 2026. Read 2026-10-22.
  7. Elsner B, et al. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020. Read 2026-10-22.
  8. Horvath JC, Forte JD, Carter O. Quantitative Review Finds No Evidence of Cognitive Effects in Healthy Populations From Single-session Transcranial Direct Current Stimulation (tDCS). Brain Stimul. 2015. Read 2026-10-22.
  9. Tang Y, et al. Effects of transcranial alternating current stimulation on cognitive function in older adults: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci. 2025. Read 2026-10-22.
  10. Horvath JC, Forte JD, Carter O. Evidence that transcranial direct current stimulation (tDCS) generates little-to-no reliable neurophysiologic effect beyond MEP amplitude modulation in healthy human subjects: A systematic review. Neuropsychologia. 2015. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.